Anton_Medvedev / Shutterstock.com
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver
Although not strictly speaking an experimental use exemption, there is one further means by which the production of medicinal products is exempted from infringement, namely, the Supplementary Protection Certificate (SPC) manufacturing waiver.
SPCs provide an extension to the period of exclusivity provided by a patent, of up to five years, for pharmaceutical products or plant protection products. They are intended to compensate the patent owner for the time required to obtain marketing authorisation for the product.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Marks & Clerk, SPC manufacturing, stockpiling, infringement, patents, experimental use, Brexit, life sciences